What is the difference between Vyvanse (Lisdexamfetamine) and Lisdexamfetamine?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 20, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Lisdexamfetamine and Vyvanse Are the Same Medication

Lisdexamfetamine and Vyvanse are identical—Vyvanse is simply the brand name for lisdexamfetamine dimesylate. There is no clinical difference between them; they refer to the same prodrug formulation 1.

Understanding the Medication

Lisdexamfetamine is a prodrug that requires metabolic conversion to become active:

  • The medication consists of dextroamphetamine covalently bonded to the amino acid L-lysine 2, 3, 4
  • After oral ingestion, red blood cells hydrolyze lisdexamfetamine to release the active component dextroamphetamine and L-lysine 1
  • The parent compound (lisdexamfetamine) itself is therapeutically inactive and does not bind to dopamine or norepinephrine reuptake sites 1, 4

Pharmacokinetic Profile

The prodrug design creates a unique absorption pattern:

  • Lisdexamfetamine reaches peak plasma concentration at approximately 1 hour post-dose 1
  • Active dextroamphetamine reaches peak concentration at 3.5-4.4 hours post-dose, depending on formulation 1
  • The plasma half-life of lisdexamfetamine is less than 1 hour, while dextroamphetamine has a half-life of 8.6-11.3 hours 1
  • This rate-limited enzymatic conversion provides approximately 12 hours of therapeutic effect with once-daily dosing 5

Clinical Advantages of the Prodrug Design

The prodrug formulation offers reduced abuse potential compared to immediate-release amphetamines:

  • The American Academy of Pediatrics suggests lisdexamfetamine may be preferred in adolescents due to lower abuse potential 2
  • The medication is only activated after ingestion through metabolic hydrolysis, making extraction of the stimulant component more difficult 2
  • Pharmacodynamic studies in adult stimulant abusers showed 50-100 mg doses of lisdexamfetamine had less likability than 40 mg immediate-release dextroamphetamine 4

Approved Indications

Lisdexamfetamine (Vyvanse) has two FDA-approved indications:

  • Treatment of ADHD in adults and pediatric patients 6 years and older 1
  • Treatment of moderate to severe binge eating disorder (BED) in adults 1, 6

Dosing Considerations

Standard dosing follows a titration schedule:

  • Starting dose is 30 mg once daily in the morning for both ADHD and BED 1
  • For ADHD: titrate in 10-20 mg increments at weekly intervals to maximum 70 mg daily 1
  • For BED: titrate in 20 mg increments weekly to target dose of 50-70 mg daily 1
  • The medication can be taken with or without food, though food delays time to peak concentration by approximately 1 hour without affecting overall exposure 1

Available Formulations

Multiple formulation options exist under the Vyvanse brand:

  • Capsules available in 10,20,30,40,50,60, and 70 mg strengths 1
  • Chewable tablets provide bioequivalent dextroamphetamine exposure to capsules on a mg-per-mg basis 1
  • Capsules can be opened and contents mixed with yogurt, water, or orange juice if swallowing is difficult 1

Important Clinical Caveat

The terms are used interchangeably in clinical practice and medical literature:

  • When prescribing, "lisdexamfetamine" refers to the generic name while "Vyvanse" is the brand name 6, 7
  • Generic formulations of lisdexamfetamine dimesylate are now available and are therapeutically equivalent to brand-name Vyvanse 1
  • All formulations—whether branded as Vyvanse or prescribed as generic lisdexamfetamine—contain the same active prodrug compound 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Placental Transfer of Vyvanse

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Lisdexamfetamine.

Paediatric drugs, 2007

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.